<DOC>
	<DOC>NCT01233232</DOC>
	<brief_summary>The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease</brief_summary>
	<brief_title>A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Bronchitis, Chronic</mesh_term>
	<criteria>Clinical diagnosis of COPD with symptoms for more than one year before screening Body mass index of 1830 kg/m2 and weight of 50100kg Current or exsmokers with a smoking history of at least 10 pack years (1 pack year = tobacco consumption corresponding to 20 cigarettes smoked per day for one year) at screening FEV1 of 30% or above and less than 80% of the predicted normal value postbronchodilator at screening FEV1/FVC less than 70% postbronchodilator at screening Any clinically significant disease or disorder Exacerbation of COPD which was not resolved within 30 days of first dosing Patients who have received live or liveattenuated vaccine in the 2 weeks prior to first dosing Asthma and any current respiratory tract disorder other than COPD which is considered to be clinically significant Disease history suggesting reduced or abnormal immune function other than that related to COPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease, Neutrophil, Respiratory Disease</keyword>
</DOC>